JANX

Janux Therapeutics, Inc. [JANX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

JANX Stock Summary

Top 10 Correlated ETFs

JANX


Top 10 Correlated Stocks

JANX


In the News

10:55 28 Mar 2024 JANX

Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade

The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

01:44 28 Mar 2024 JANX

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc  JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.

09:45 28 Mar 2024 JANX

2 Stocks That Have More Than Tripled This Year: Are They Buys?

Viking Therapeutics and Janux Therapeutics are flying high on the back of positive data readouts. However, there is a long road ahead and plenty of potential risks for both of these mid-cap biotechs.

06:56 28 Mar 2024 JANX

After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?

Janux Therapeutics just reported some phenomenal early Phase 1 data. It still needs to confirm the value of its programs and platform.

10:31 28 Mar 2024 JANX

5 Stocks That More Than Doubled in February

Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.

09:51 28 Mar 2024 JANX

Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics, Inc. (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

05:15 28 Mar 2024 JANX

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032.

07:46 28 Mar 2024 JANX

Why Is Janux Therapeutics (JANX) Stock Up 108% Today?

Janux Therapeutics (NASDAQ: JANX ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company posted interim results from two studies. According to a press release from Janux Therapeutics, both JANX007 and JANX008 are showing encouraging efficacy and safety data in their clinical trials.

03:41 28 Mar 2024 JANX

Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?

Janux Therapeutics, Inc. (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

11:18 28 Mar 2024 JANX

Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

JANX Financial details

Company Rating
Neutral
Market Cap
2.04B
Income
-58.29M
Revenue
8.08M
Book val./share
7.38
Cash/share
7.37
Dividend
-
Dividend %
-
Employees
64
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-9.18
Forward P/E
-21.86
PEG
-40.09
P/S
59.71
P/B
1.43
P/C
5.1
P/FCF
-11.54
Quick Ratio
24.17
Current Ratio
24.55
Debt / Equity
0.07
LT Debt / Equity
0.07
-
-
EPS (TTM)
-1.34
EPS next Y
-1.72
EPS next Q
-0.37
EPS this Y
0.76%
EPS next Y
28.66%
EPS next 5Y
15.97%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-2.22%
EPS Q/Q
-
-
-
-
-
SMA20
18.18%
SMA50
290%
SMA100
550%
Inst Own
65.18%
Inst Trans
0.89%
ROA
-14%
ROE
-17%
ROC
-0.2%
Gross Margin
100%
Oper. Margin
-887%
Profit Margin
-644%
Payout
-
Shs Outstand
51.66M
Shs Float
32.38M
-
-
-
-
Target Price
-
52W Range
5.65-58.694
52W High
-35.18%
52W Low
+651.9%
RSI
60
Rel Volume
0.02
Avg Volume
701.85K
Volume
14.39K
Perf Week
-3.92%
Perf Month
295.74%
Perf Quarter
274.45%
Perf Half Y
287.18%
-
-
-
-
Beta
4.304
-
-
Volatility
0.8%, 11.68%
Prev Close
-0.86%
Price
37.595
Change
-4.31%

JANX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.150.210.18
Net income per share
-0.66-0.42-1.38-1.31-1.32
Operating cash flow per share
-0.6-0.35-0.72-1.04-1.15
Free cash flow per share
-0.6-0.35-0.78-1.19-1.19
Cash per share
0.10.6315.947.897.82
Book value per share
-1.24-1.1715.577.737.82
Tangible book value per share
-1.24-1.1715.577.737.82
Share holders equity per share
-1.24-1.1715.577.737.82
Interest debt per share
1.280.080.010.710.56
Market cap
161.34M313.69M464.25M546.16M472.29M
Enterprise value
164.68M305.87M428.86M520.03M477.63M
P/E ratio
-38.08-59.69-14.26-10.09-8.1
Price to sales ratio
00127.6563.4258.43
POCF ratio
-42.15-71.8-27.35-12.72-9.34
PFCF ratio
-42.15-71.8-25.15-11.06-9.01
P/B Ratio
-20.31-21.431.271.71.37
PTB ratio
-20.31-21.431.271.71.37
EV to sales
00117.9260.3859.09
Enterprise value over EBITDA
-43.74-46.59-13.02-7.75-6.72
EV to operating cash flow
-43.02-70.01-25.26-12.12-9.44
EV to free cash flow
-43.02-70.01-23.23-10.53-9.11
Earnings yield
-0.03-0.02-0.07-0.1-0.12
Free cash flow yield
-0.02-0.01-0.04-0.09-0.11
Debt to equity
-1.01-0.0500.080.07
Debt to assets
11.780.0500.070.06
Net debt to EBITDA
-0.891.191.070.39-0.08
Current ratio
0.145.0529.4620.1426.8
Interest coverage
-16.18-23.510-16.640
Income quality
0.960.640.520.680.87
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
002.842.583.23
Research and developement to revenue
007.216.216.79
Intangibles to total assets
00000
Capex to operating cash flow
000.090.150.04
Capex to revenue
00-0.41-0.75-0.23
Capex to depreciation
00-13.12-7.66-0.95
Stock based compensation to revenue
001.922.47
Graham number
4.293.3422.0215.0715.27
ROIC
-76.740.27-0.09-0.16-0.19
Return on tangible assets
-6.24-0.32-0.09-0.15-0.15
Graham Net
-1.24-1.3715.366.857.01
Working capital
-3.97M12.88M364.22M315.93M336.21M
Tangible asset value
-7.94M-14.64M366.33M320.74M344.35M
Net current asset value
-7.97M-14.79M363.52M289.17M313.18M
Invested capital
-1.01-0.0500.080.07
Average receivables
04M4.1M450K1.45M
Average payables
0347.5K1.44M2.31M2.29M
Average inventory
00-100K-450K-1.45M
Days sales outstanding
0020.0729.6799.34
Days payables outstanding
16.24K12.02K7.94K937.02452.56
Days of inventory on hand
00-646.02-303.8-410.74
Receivables turnover
0018.1912.33.67
Payables turnover
0.020.030.050.390.81
Inventory turnover
00-0.57-1.2-0.89
ROE
0.530.36-0.09-0.17-0.17
Capex per share
00-0.06-0.16-0.04

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.070.050.030.060.05
Net income per share
-0.27-0.42-0.42-0.25-0.25
Operating cash flow per share
-0.29-0.33-0.36-0.26-0.21
Free cash flow per share
-0.34-0.34-0.37-0.27-0.22
Cash per share
7.867.597.257.657.37
Book value per share
7.717.457.167.637.38
Tangible book value per share
7.717.457.167.637.38
Share holders equity per share
7.717.457.167.637.38
Interest debt per share
0.660.530.60.540.53
Market cap
547.66M505.34M496.6M460.74M500.92M
Enterprise value
521.54M500.53M488.12M468.48M506.25M
P/E ratio
-12.16-7.24-7.09-9.96-10.65
Price to sales ratio
192.5246.75469.82183.05203.54
POCF ratio
-45.97-36.33-32.99-39.35-50.59
PFCF ratio
-39.21-35.6-31.76-37.83-48.09
P/B Ratio
1.711.621.661.321.45
PTB ratio
1.711.621.661.321.45
EV to sales
183.32244.4461.8186.13205.71
Enterprise value over EBITDA
-28.55-24.68-24.07-29.63-32.44
EV to operating cash flow
-43.78-35.98-32.42-40.01-51.13
EV to free cash flow
-37.34-35.26-31.22-38.47-48.6
Earnings yield
-0.02-0.03-0.04-0.03-0.02
Free cash flow yield
-0.03-0.03-0.03-0.03-0.02
Debt to equity
0.080.080.080.070.07
Debt to assets
0.070.070.070.060.06
Net debt to EBITDA
1.430.240.42-0.49-0.34
Current ratio
20.1419.9517.2824.5526.8
Interest coverage
-8.36.19000
Income quality
0.740.80.861.010.84
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
23.166.512.562.58
Research and developement to revenue
5.427.7514.124.724.97
Intangibles to total assets
00000
Capex to operating cash flow
0.170.020.040.040.05
Capex to revenue
-0.72-0.14-0.55-0.19-0.21
Capex to depreciation
-5.1-0.63-1.23-0.94-0.97
Stock based compensation to revenue
1.482.675.21.811.82
Graham number
6.868.378.216.596.47
ROIC
-0.03-0.05-0.06-0.04-0.04
Return on tangible assets
-0.03-0.05-0.05-0.03-0.03
Graham Net
6.836.66.256.836.61
Working capital
315.93M305.29M291.4M340.72M336.21M
Tangible asset value
320.74M311.26M299.47M348.95M344.35M
Net current asset value
289.17M279.71M267.27M317.29M313.18M
Invested capital
0.080.080.080.070.07
Average receivables
600K725K1.13M1.6M1.95M
Average payables
2.51M2.11M1.98M2.21M2.46M
Average inventory
-350K-350K-750K-1.6M-1.95M
Days sales outstanding
22.1432.96127.7260.7980.46
Days payables outstanding
482.16407.48364.97450.9410.85
Days of inventory on hand
-156.330-286.62-306-372.88
Receivables turnover
4.062.730.71.481.12
Payables turnover
0.190.220.250.20.22
Inventory turnover
-0.580-0.31-0.29-0.24
ROE
-0.04-0.06-0.06-0.03-0.03
Capex per share
-0.05-0.01-0.01-0.01-0.01

JANX Frequently Asked Questions

What is Janux Therapeutics, Inc. stock symbol ?

Janux Therapeutics, Inc. is a US stock , located in La jolla of Ca and trading under the symbol JANX

What is Janux Therapeutics, Inc. stock quote today ?

Janux Therapeutics, Inc. stock price is $37.595 today.

Is Janux Therapeutics, Inc. stock public?

Yes, Janux Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap